losing $28mm per quarter in cash with only 3 quarters of cash left. They will need another offering pronto. drug is in Phase III with a now crowded market with the approval of Indoplan pending. They would need to have some unique mode of action to overcome the 3 leaders and you can bet they don't have it. too risky for the prudent.